In the Australian therapeutic trial in patients with mild diastolic hypertension, univariate analysis of possible prognostic characteristics (covariates) at the time of entry into the study showed a hi^gher incidence of trial end points. mainly events due to ischemic heart disease and cerebrovascular disease, in older subjects, men, cigarette smokers, and those with higher systolic blood pressures and lower body mass indexes than in their complementary groups. There was a lower
incidence of these events in actively treated subjects than in control subjects at both high and low levels of incidence of each covariate considered, but treatment benefit was most marked in those with lower serum cholesterol levels and lower systolic blood pressures. Multivariate regression analyses of data fronm men and women separately, performed with the Cox proportional-hazards model, confirmed that the incidence of trial end points increased with age and with systolic blood pressure, and showed higher rates in cigarette smokers, which increased markedly with decreasing body weight. With respect to the effects of treatnient. the multivariate analysis showed an increasing benefit with decreasing body weight in smokers. The apparent relationship of treatment benefit to systolic blood pressure in the univariate analysis did not reach statistical significance in the multivariate analysis. The greater benefit from treatment related to lower levels of serum cholesterol found in the univariate analysis was also found in several preliminary multivariate analyses, but did not reach statistical significance in the final model. However, this relationship should be tested in other therapeutic trials in progress or recently completed. Similar results were found when ischemic heart disease events alone were considered. This analysis of covariates did not identify any group of subjects in whom drug treatment was not indicated, but as described in an earlier article, approximately half of the patients in the placebo group were normotensive at 3 years. and niost by 4 months. Thus, a period of observation of sonie 4 months should identify a large number ol suspected mild hypertensives who do not require antihypertensive drug treatment.
Circulation 69, No. 4, 668-676, 1984. THE AUSTRALIAN THERAPEUTIC TRIAL in mild hypertension was a controlled trial in which subjects randomly assigned to receive antihypertensive medication or placebo tablets continued on their regimens, as randomized, for periods of up to 6 years. On the trial characteristics (covariates) that might be associated with prognosis were recorded for each subject and the similar distribution of these covariates in the active and placebo groups indicated that the randomization procedure was satisfactory.
The opportunity has now been taken to consider possible associations between these covariates, the occurrence of trial end points (TEPs), and the results of treatment. Since the study was not designed to test such associations, and there were relatively small numbers of subjects in some covariate sets, e.g., smokers and women, the conclusions cannot be considered to be definitive. However, since the results complement those previously published and may be of interest for comparison with results of other trials in patients with mild hypertension, they are now reported. Material and methods The design. conduct, and primary results of the study have been reported. [1] [2] [3] The analysis was based on experience with 3427 subjects who continued on their randomly assigned regi-mens for an average of 3.1 years, thus qualifying as an "ontreatment" analysis, as described in previous articles. We believe this is preferable to the alternative "intention-to-treat" analysis, which examines the total experience of subjects (for an average of 4.1 years), including any continuation after premature withdrawal from the randomly assigned regimens and the possible institution of other forms of treatment. Although the analysis by intention to treat allows the possibility of bias due to differing reasons for premature withdrawal between the actively treated and placebo groups to be avoided, it introduces bias by including TEPs of subjects in the active group after they have stopped treatment and by including the experience of subjects on placebo who are prematurely withdrawn and given active treatment by their own doctors. These matters were discussed in the earlier report,' in which it was nevertheless found by both forms of analysis that there was significant benefit from treatment. The present analysis was performed for all 218 TEPs combined and was performed separately for the 158 ischemic heart disease events. Numbers of TEPs in other diagnostic categories were too small for separate analyses of this kind.
The covariates considered were age, sex, cigarette smoking, serum cholesterol level, body mass index (BMI), i.e., (weight in g)/(height in cm)', systolic blood pressure (SBP), and diastolic blood pressure (DBP) at screening. The number of covariates and the interactions between them that could be considered in the multivariate analysis were restricted by computer space limitations and the covariates chosen were considered the most important of all those measured. Blood pressure at screening was imcasured by trained observers using randomi-zero sphygmomanometers. Subjects were seated for 5 min before measurement. Pressures were taken twice at each of two screening visits 2 weeks apart and "screening pressure" was taken as the mean of the four readings. Serum cholesterol was estimated in one laboratory throughout the study. At each of the four centers blood was taken and serum separated within 1 hr. Frozen samples were stored, batched, packed in ice, and dispatched by air to the laboratory. Estimation of cholesterol level was made on an isopropanol extract of the serum by the method of Levine and Zak.4 Quality control was maintained with, foreach batch of 20 specimens. an aliquot of reference serum that was prepared and lyophilyzed at the beginning of the study.
Information for each subject on the type and extent of smoking was collected at entry, but for this analysis subjects were simply divided into cigarette smokers (regardless of the number of cigarettes smoked daily) and noncigarette smokers. Weight and height were measured with subjects in street clothes without coat or shoes.
Statistical methods. The apparent relationship of covariates to the incidence of TEPs was first examined by comparing rates in the active and placebo groups for high and low levels of each covariate, i.e., a univariate dichotomous analysis of rates. Relationships were examined for age (cut at 50 years), sex, cigarette smoking and noncigarette smoking, serum cholesterol level (cut at 220 mg/dl), BMI (cut at 2.6), SBP (cut at 160 mm Hg), and DBP (cut at 100 mm Hg). These cut points were chosen as biologically relevant, and for each covariate apart from sex and smoking, there were substantial and roughly equal numbers above and below the cut.
Since results obtained with this univariate approach may be misleading, multivariate regression analysis in which interaction effects were included was undertaken with the Cox proportional-hazards models (see Appendix).
The multivariate regression analysis was applied in a -stepdown" fashion. This procedure was adopted to find a regression equation that included only those variables contributing significantly to the prediction of TEPs. First, a regression equation was fitted with the whole set of variables to be considered. Then a series of equations was fitted in which each variable was omitted in turn and thus the contribution of each to the prediction established. If all the variables had been significant at the 5% level then the step-down process would not have been needed and the regression equation in which the full set of variables is used would have been employed for prediction of TEPs. In fact, not all were significant and the first step down was to use that equation from which the least significant variable had been eliminated. From this point the process continued with, at each step, an equation with one variable fewer being fitted, always providing that the variable eliminated was not significant at the 5% level. Thus, eventually a point was reached at which each variable retained made a contribution to the prediction that was significant at the 5% level.
At this point the step-down procedure was terminated; the regression equation so derived is referred to in this report as the ',significant-term" model. To this significant-term model were added the corresponding lower order effects to yield the hierarchical model (see Appendix) used for prediction of rates.
The explanatory variables considered in the analysis were selected from treatment, the six main covariates listed above (excluding sex), the 21 second-order interactions, and the likely third-order interactions by a series of exploratory analyses performed on data from men and women separately, as described in the Appendix. Also the 17 explanatory variables selected are listed in the Appendix. The exploratory analysis of the age effect showed that of age, age2. and age3, the last had the strongest association with TEP occurrence. The addition of age and/or age2 did not significantly improve the fit over that with age3 alone and the latter, taken as age3/l00 for computational convenience and abbreviated as age , was considered a main effect.
The multivariate analysis was done on the male and female components of the trial population separately, but in parallel, so that the explanatory variables were eliminated according to the joint experience of men and women, providing they were not significant in either sex. The explanatory variables retained in the significant-terms model thus were ones that contributed significantly to the occurrence of TEPs irrespective of the others used in this analysis.
Results
The grouped frequency distributions, means, and SDs of the covariates under consideration are shown for men and women in table 1. No differences (at the 5C/% level) between the active treatment and placebo groups (men and women considered separately) were demonstrated by the Kolmogorov-Smirnov test. 6 Comparison of means by the t test also showed no differences, except for a significantly lower mean BMI in men in the placebo compared with those in the active treatment group.
The results of univariate dichotomous analysis of rates are shown in table 2. Looking first at the placebo group, it can be seen that within the covariate sets, higher rates of incidence of TEPs were found in the older age group, the men, those with higher blood pressures, cigarette smokers, and those with lower BMIs. Serum cholesterol level showed no discriminating power. Results of comparisons of the rates for each Vol. 69, No. 4, April 1984 dichotomous pair suggest that age had the strongest relationship with TEP occurrence, followed, in order, by smoking, SBP, sex, BMI, and DBP. The results were similar when data from men and women were considered separately. The rates of occurrence of TEPs were lower in the active treatment groups than in the corresponding placebo groups for both subdivisions of all covariates, but the differences were by no means uniform, suggesting that interactions between covariates and treatment may be operative. The most striking results were in relation to serum cholesterol level and SBP; for both of these the apparent relative benefit from treatment was very much greater at lower than at higher levels of the covariate. In absolute terms the apparent benefit from active treatment was greatest in subjects with low cholesterol levels and was greater than the overall average in smokers and those with lower BMIs, those with lower SBPs, and older subjects.
The step-down multivariate analyses resulted in the ultimate retention of age, SBP, an interaction between treatment and smoking, and an interaction between treatment, smoking, and BMI as significant explanatory variables contributing to the occurrence of TEPs. Thus, the effectiveness of treatment was significantly related to smoking and BMI. The predicted rates of precisely, age3. The predicted rate increases by 50% and 60% as age increases from 40 to 50 years and by 80% and 100% as it increases from 50 to 60 years for men and women, respectively, regardless of BMI, smoking status, or whether the subject is in the active or placebo group (table 3, figure 1 ). Age can thus be Rates are for age 50 years and average BMI. regarded as a risk factor. The benefit from treatment is apparent at all ages. Sex. The analysis shows that in the placebo groups, rates for men are generally higher than those for women regardless of other covariates, but the difference becomes less at lower BMIs and among smokers. Thin female smokers have rates approximately the same as thin male smokers. The benefit from treatment is greater for women than for men, especially in smokers. Considering those 60 years old, for example, the TEP rate in untreated female smokers with low BMIs is predicted by the model to be 90 per 1000 person-years and this is reduced to 15 per 1000 person-years with treatment, a level similar to that in actively treated female nonsmokers of the same age and BMI. In men, treatment of smokers also results in reduction in rates, but to a level that is still some 60% higher than in their actively treated, nonsmoking counterparts.
In an earlier article' in which the overall results of the study were reported, it was observed that although there was an approximately 30% lower rate in actively treated women compared with women in the placebo group, the difference did not reach the 5% level of significance. This conclusion was based on the exact test of significance described in that report. A univariate analysis of TEPs in women, using the Cox proportional-hazards model,' which uses more information, showed the treatment effect to be significant at the 5% level and this is confirmed by the results of the present multivariate analysis. Blood Pressure. SBP at screening proved to be significantly associated with the occurrence of clinical events, but for DBP there was no such association. A higher SBP, which reflects higher pulse pressure, is probably associated with atherosclerotic changes in the vessels. The incidence of TEPs more than doubled with an increase of SBP from 120 to 195 mm Hg, regardless of sex, smoking habits, age, or BMI. The relative treatment effect, however, was unrelated to screening SBP (table 4; figure 2 ).
The lack of any demonstrable relationship of DBP to the incidence of cardiovascular events in this study may be explained by the narrow gating of DBP used in selecting the mildly hypertensive population and the fact that SBP was included in the analysis, given the high correlation between DBP and SBP.
In a report on the interim results of the study,7 on the basis of which the decision to stop the trial was made, it was stated that the benefit of treatment was limited to subjects who had an entry DBP B 100 mm Hg. ("Entry" DBP was the DBP recorded when tablets [active or placebo] were first prescribed, i.e., at the first postscreening visit at which DBP was again B95 mm Hg, which in some instances was weeks, months, or years after screening.) At the close of the study, when an additional 32 TEPs had been registered, it was found that the reduction in TEP rate was present and significant at the 5% level in subjects with entry DBPs both above and below 100 mm Hg. For this study, subjects were classified according to screening pressure, a more practical prognostic index that allows the variable delay in time between measurements to be avoided. In this multivariate analysis, it has been found that benefit from treatment was not significantly related to screening DBP. This may be explained by the narrow gating referred to above and also to the finding reported in an earlier article3 that the outcome in this intervention study was related not to initial levels of pressure but to levels achieved throughout the study. Cholesterol. The lack of association between high cholesterol levels and clinical events in subjects on placebo is contrary to the well-established relationship observed in prospective studies in the general population. This may be due to the relatively short period of observation (average 3.1 years) and the higher age range of our subjects.
The multivariate analysis did not confirm the results of the univariate analysis, which suggested that active treatment of mild hypertension was much more effective when cholesterol levels were lower. However, it is worthy of note that the interaction between cholesterol level and treatment was among the last to be eliminated in the step-down process. Furthermore, a multivariate analysis carried out previously with data from both sexes combined but from nonsmokers and smokers separately showed a statistically significant inverse relationship between the initial serum cholesterol level and benefit from treatment in nonsmokers. The methods of these two analyses were the same except that age, rather than age', was used in the earlier one. These results suggest that treatment of hypertension may be less effective in subjects with high serum cholesterol levels. This may be explained by the fact that high serum cholesterol is a marker for high risk of atherosclerosis and particularly ischemic heart disease, which is less likely to be affected by antihypertensive treatment. It is of interest that the recent report of the Multiple Risk Factor Intervention Trial in the United States8 also described a markedly lower incidence of events in intensively treated compared with referred care, nonsmoking, hypertensive subjects with serum cholesterol levels below 250 mg/dl (3.2 vs 17.5 per 1000) than in those with higher levels (19.4 vs 16.4 per 1000). The design of that study led to inclusion of a high proportion of subjects with high serum cholesterol levels and this may account to some extent for the lack of benefit overall found in the intensive care vs the referred care group.
Body mass. The only significant contribution of body mass to the prediction of rates of TEPs in this study would seem to be through its interaction with smoking, as described below. As noted in the Results section, in men the mean BMI at screening in the active group was significantly higher than in the placebo group. However, since effect of treatment was controlled for BMI and vice versa, the general conclusion is not invalidated.
Vol. 69, No. 4, April 1984 Smoking. In both the univariate analysis (table 2) and the multivariate analysis (tables 3 and 4; figures 1 and 2), smoking was associated with increased risk. However, the analysis showed that this relationship was dependent on BMI, such that the risk in untreated subjects and the benefit from treatment increased with decreasing BMI, as shown graphically in figure 1 , which illustrates results shown in table 3. Whereas TEP occurrence in nonsmokers was not related to BMI, in smokers in the placebo group there was a marked inverse relationship that appears to have been reduced by active treatment of hypertension.
A poorer prognosis in smokers of low compared with those of high body weight has been noted previously by Whyte,9 who reviewed data from the Chicago Peoples Gas Company Study. It seems likely that the decreasing body weight reflects the extent of damage to health resulting from smoking, although why this should interact so strikingly with hypertension and be favorably affected by antihypertensive treatment is not clear.
Ischemic heart disease. The multivariate analysis described above was done in terms of all TEPs. Since 72% of all TEPs were due to ischemic heart disease, the outcome would seem to depend largely on the occurrence of and benefit from treatment for this condition. Separate analyses have been undertaken for ischemic heart disease end points and these have given results similar to those of the analysis for total end points (see Appendix). Results obtained with univariate analysis reported previously' showed 20% fewer ischemic heart disease events in actively treated subjects in the on-treatment analysis and 10% fewer events in the intention-to-treat analysis. The differences were not statistically significant and no conclusion was drawn as to the effect of antihypertensive treatment on ischemic heart disease. The multivariate analysis described in this report showed a reduction in ischemic heart disease events with treatment, but this reached statistical significance only in smokers, among whom it was inversely related to BMI.
The number of TEPs was too small to do similar analyses for other categories of TEPs, such as acute myocardial infarction (of which there were 45 events) or cerebrovascular disease (of which there were 37 events). It cannot be assumed that the conclusions for the relationships of covariates to total TEPs and to ischemic heart disease hold for these diagnostic categories. The observations reported relate to covariates at the start of the randomized regimen. There was an insufficient number of subjects in this trial to examine the effect of changes in the levels of these covariates during the course of the antihypertensive treatment.
As stated in the introduction, there were no firm a priori hypotheses about the benefit of treatment (or lack of it) in subsets of the population and any significant effects that have shown up in the analyses described in this article need confirmation from similar but independent and preferably larger bodies of data. With these reservations, we draw the following tentative conclusions from the study.
Most risk factors for cardiovascular disease in the untreated mildly hypertensive subjects of this study are similar to those previously reported in general populations, with the exception of serum cholesterol level. Risk in smokers is inversely related to body weight.
One of the objects of undertaking this analysis was to seek leads to identification of subjects with mild hypertension in whom pharmacologic treatment would or would not be beneficial. The results suggest that such treatment is beneficial in men and women, at all ages, in smokers and nonsmokers, and in those with high and low blood pressures, body masses, and serum cholesterol levels at screening. However, the benefit of treatment would seem to be much greater than average in some subsets, particularly in smokers with low levels of body mass and perhaps in those with low levels of cholesterol. Smokers who are obese would seem to benefit least, and perhaps not at all.
The risk of ischemic heart disease in subjects with mild hypertension is reduced by antihypertensive treatment in smokers. Fewer events were also observed with treatment in nonsmokers, but the difference was not statistically significant.
Although we were unable to identify, by any covariate considered, subjects with mild hypertension who might be safely spared pharmacologic treatment, one of the most important findings of the study, which was previously reported,3 was that almost half of our subjects in the placebo group with mild hypertension at screening experienced a fall in pressure to less than 95 mm Hg by 3 years, most of them within 4 months of the beginning of observation. Such subjects clearly do not require drug therapy. This suggests that repeated blood pressure measurements over an observation period of some 4 months (during which nonpharmacologic methods may be tried) can identify a large proportion of subjects with suspected mild hypertension in whom drug therapy can be withheld. Appendix: multivariate analysis* The Cox regression model' is specifically designed for the analysis of survival data when a set of baseline covariates (or explanatory variables), e.g.. age, sex, blood pressure, treatment group, etc., is known for each individual and when individual survival time may be either exact (time to TEP) or censored (time to withdrawal, loss to follow-up, or end of trial without TEP).
The analysis is carried out in terms of the hazard function that is the instantaneous probability of a TEP occurring at a given time. This hazard is in turn a function of an underlying or population hazard function (the form of which is unspecified), the explanatory variables, and associated unknown regression coefficients. The explanatory variables affect the hazard in a multiplicative way and thus the model is termed a proportionalhazards model. Breslow (see the discussion following Cox5) amended the model by assuming the hazard function to be a step function with steps at each distinct survival time (time at which at least one TEP occurred). This leads to a technical simplification in the model and has been adopted throughout our application of the model. The regression coefficients and then the underlying hazard function were estimated with maximum-likelihood procedures and iteration by the Newton-Raphson method. Significance tests for the regression coefficients are based on the asymptotic theory of Cox.5 The test used in our analysis was the generalized likelihood ratio chi-squared test given by Cox on p 191 of his article.
The multivariate analysis was carried out in a step-down fashion as described in Methods. Computer limitations (available core) restricted the number of explanatory variables and 17 was taken to be the upper limit. However, this limit was not always reached because when the set of explanatory variables included a large number of highly correlated interactions, multicollinearity sometimes led to the situation in which the regression coefficients could not be estimated and the Cox run did not converge. Some runs on subsets with relatively small numbers of TEPs also failed to converge.
Although this trial was designed to test the benefit of treatment "across the board" in a mixed male and female population with no separate analysis by sex, age groups, etc., it was decided to do this covariate analysis by the Cox method on data from men and women separately since most of the covariates measured were correlated with sex. In particular, cholesterol increased with age in women but not in men, smoking patterns and BMI distributions were different in the two sexes, and the cradient of TEPs with age was steeper for women than for men. Separate analyses for men and women removed the need to consider interactions of sex with all other main and interaction etfects. It would have been advantageous to further divide in terms of smoking status, thus removing all smoking interactions. but the resulting subsets would have been too small.
To select the explanatory variables for the first step-down analysis run. each of the 21 possible two-way interactions was added in turn to the seven main effects (treatment, age smoking, cholesterol level. BMI, SBP, and DBP) for men and women separately. The interactions were all products of two of the seven main effects, five of which were continuous and two of which were represented by 0-1 dummy variables (treatment 10 active. 1 placebo] and smoking 10 nonsmoker, I smoker]).
TRhus, each two-way interaction was tested, controlling for all seven main effects, and only two, treatment x cholesterol (in women) and smoking x BMI (in both sexes), showed up as significant at the 5% level. These were therefore included in the tirst step-down run.
To see whether any third-order interactions should be considered, the treatment x cholesterol and smoking x BMI interactions were tested in the smoking/nonsmoking and active/placebo subpopulations. respectively. Treatment x cholesterol was significant only in nonsmokers (5% level for women, almost 10% for men). and smoking x BMI only in placebo subjects CIRCULATION *Prepared by Camilla Fazekas de St. Groth and K. R. W. Brewer.
(2.5% for women, 5% for men), indicating that the three-way interactions treatment x smoking x cholesterol and treatment x smoking x BMI should.be included.
The DBP main effect was omitted from the step-down analysis since when controlling for SBP and the other five main effects it was not significant and since there were no two-way interactions with DBP that were significant in the above runs controlling for all other main effects.
To the six main effects (excluding DBP) were added treatment x smoking x cholesterol and treatment x smoking x BMI and their corresponding lower order two-way interactions: treatment x smoking, treatment x cholesterol, smoking x cholesterol, treatment x BMI, and smoking x BMI, giving a total of 13 explanatory variables for the first step-down analysis.
Since it was technically possible within the computer limitations to include up to 17 explanatory variables, seven additional twoway interactions were considered for inclusion. Since the treatment effect was of particular interest, those interactions with treatment not already included (treatment x SBP and age3 x treatment) were added. Smoking x SBP was added because of a possible effect of smoking on blood pressure. Since the age effect showed the strongest association with TEP occurrence, the four remaining interactions involving age were considered (i.e., with smoking, SBP, BMI, and cholesterol level). Of these, only age3 x cholesterol gave a combination that converged in both sexes, a necessary condition for the'start of the step-down analysis as described below, and was thus included giving a total of 17 variables.
Although the step-down analysis was carried out on the data from men and women separately, no explanatory variable. was eliminated at any step if it was significant in either sex. Further, a chi-squared test statistic with two degrees of freedom was formed by adding the male and female test statistics and the corresponding variable was only eliminated if it was not significant at the 5% level. When nonconvergence prevented the calculation of a test statistic, the corresponding explanatory variable was not eliminated at that stage.
The explanatory variables were eliminated in the following order: smoking, smoking x cholesterol, treatment x smoking x cholesterol, smoking x SBP, treatment x BMI, BMI, age3 x cholesterol, smoking x BMI, treatment x SBP, treatment, cholesterol, treatment x cholesterol, age3 x treatment. The resulting significant-terms model thus included the remaining four explanatory variables: age3, SBP, treatment x smoking, and treatment x smoking x BMI. To these were added the corresponding lower order effects to give the final hierarchical model: age3, treatment, smoking, BMI, SBP, treatment x smoking, treatment x BMI, smoking x BMI, treatment x smoking x BMI. These lower order effects were added back into the model of significant terms resulting from the stepdown analysis because the existence of any significant interaction implied that the corresponding main effects and lower order interactions also contributed, although not in the statistically significant sense.
To test the overall adequacy of the hierarchical models, "crude" residuals as described by Cox and Snell'0 were calculated and the corresponding cumulative hazard functions plotted." The relationships were approximately linear, indicating that the models described the effects of covariates on the occurence of TEP adequately.
The regression coefficients and their estimated standard errors for men and women separately are given in table 6.
A step-down analysis was carried out in the same way considering only the 158 ischemic heart disease events. Nonconvergence problems removed two effects (treatment x SBP and age3 x cholesterol) from the initial set of explanatory variables, leaving 15. The model of significant terms for all ischemic heart disease contained the same explanatory variables as for all TEPs and the regression coefficients for the corresponding hierarchical model are shown in table 7.
